Addex Therapeutics Ltd (NASDAQ:ADXN) Sees Significant Decline in Short Interest

Addex Therapeutics Ltd (NASDAQ:ADXN) saw a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 5,700 shares, a drop of 34.5% from the December 15th total of 8,700 shares. Based on an average daily volume of 39,100 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.7% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Addex Therapeutics in a report on Wednesday, October 2nd.

Addex Therapeutics Stock Performance

Shares of Addex Therapeutics stock opened at $7.59 on Thursday. Addex Therapeutics has a one year low of $6.45 and a one year high of $27.90. The company has a market cap of $8.04 million, a P/E ratio of -22.31 and a beta of 1.76. The firm has a fifty day moving average of $8.17 and a two-hundred day moving average of $8.90.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.